Abstract. In 
Introduction
The human immune response to hepatitis B virus infection is variable. Although the vast majority of people infected with hepatitis B virus respond by clearing the hepatitis B surface antigen (HBsAg)l and developing antibody to HBsAg (antiHBs IgG), a small percentage (5-10%) will not resolve the infection; viral synthesis persists, and the individual becomes a chronic carrier of HBsAg (1) . Several clinical syndromes are associated with the absent or incomplete immune response to HBsAg. Aberrant immune responses to HBsAg that result in immune complex formation and subsequent tissue deposition have been causally implicated in some cases ofcryoglobulinemia (2) , glomerulonephritis (3, 4) , and systemic necrotizing vasculitis (5, 6) . The association of the chronic HBsAg carrier state and chronic state and chronic hepatitis has also been emphasized (7, 8) and extensively investigated (reviewed, 9 and 10). The ability to evaluate the human immune response to HBsAg could provide insights into a number of clinical syndromes associated with an aberrant immune response to this agent.
Although a great deal can and has been learned about normal and aberrant regulation of specific antibody production 1. Abbreviations used in this paper: anti-HBs IgG, antibody to hepatitis B surface antigen; ELISA, enzyme-linked immunosorbent assay; FCS, fetal calf serum; HBsAg, hepatitis B surface antigen; KLH, keyhole limpet hemocyanin; MLR, mixed leukocyte reaction; PBMC, peripheral blood mononuclear cell; PWM, pokeweed mitogen; TCD, T cell depleted; TCE, T cell enriched; TT, tetanus toxoid.
after stimulation by polyclonal B cell activators (11, 12) , including anti-HBs IgG production after activation with pokeweed mitogen (PWM) (13), the dichotomy in specific antibody production after stimulation with polyclonal B cell activator versus that after stimulation with antigen has been emphasized (14, 15) . In vitro antigen-induced specific antibody production has been described in response to both nonviral (14) (15) (16) and viral antigens (17) (18) (19) , but not in response to HBsAg. The recent development and successful use of HBsAg vaccine (20) (21) (22) has provided a model for evaluating more precisely the human immune response to HBsAg. In this report we demonstrate in vitro antigen-induced specific antibody responses to HBsAg in man after immunization with HBsAg vaccine. The response is critically dependent upon the postimmunization kinetics of the circulating peripheral blood lymphocyte repertoire. The antigen-induced response also depends upon the presence of monocytes and T cells in culture. Despite the T cell dependence of the specific antibody response, no proliferative response to HBsAg could be demonstrated.
Methods
Immunization. Normal subjects, aged 21-37 yr, received 0.5-ml (20 ,gg of antigen as protein) intramuscular injections of the HBsAg vaccine (lot A-9; National Institutes of Health, Bethesda, MD) (21) . 1 and 6 mo after the initial immunization, the booster immunizations were administered. The immunizations were carried out under peer-reviewed National Institutes of Health protocols. Of the 25 normal subjects immunized, 24 had evidence of a positive serologic response, as determined by Ausab (Abbott Laboratories, Diagnostic Div., North Chicago, IL) after completion of the three shot series. The 14 normal subjects who had evidence of a positive serologic response after the first immunization were selected for study after the second and/or third immunization.
HBsAg. The HBsAg (serotype adw) was prepared from the plasma of a single donor. Highly purified 22-nm particles were prepared by sequential density gradient separation using zonal centrifugation procedures as previously described (23) . The HBsAg, at a concentration of 438 ,gg/ml protein as determined by the method of Lowry (24) , was stored at -70'C until needed and then kept at 40C while being used.
Cell separations. Peripheral blood mononuclear cells (PBMCs) were obtained from Hypaque-Ficoll gradients in the standard fashion (25) . T cell-enriched (TCE) populations were obtained by rosetting with amino-S-2 aminoethylisothiouronium bromide-treated sheep erythrocytes and passing the rosetted cells over Hypaque-Ficoll gradients (26) . After lysis of the sheep erythrocytes, the final TCE population was obtained by passage over a nylon wool column (27) . The rosettenegative cell population was used as the T cell-depleted (TCD) fraction. Monocyte depletion was accomplished by adherence to 4-mm Pyrex glass beads (Coming Glass Works, Coming Medical and Scientific Coming, NY) and passage through Sephadex G-10 (Pharmacia Fine Chemicals, Piscataway, NJ) (28) . Monocyte-depleted cell fractions contained <1 nonspecific esterase-positive cell per 100 cells counted, unless otherwise stated (28) . PBMCs irradiated with 2,000 rads were used as a source of monocytes.
Cell culture conditions. Cultures for the measurement of supernatant Ig production were performed in 1 ml RPMI 1640 with 2 mM glutamine, 10% fetal calf serum (FCS) (Gibco Laboratories, Gibco Div., Grand Island, NY) with 10 ug/ml gentamicin in 24-well flat-bottomed plates with 16-mm wells (Costar, Data Packaging, Cambridge, MA).
The PBMCs were cultured at a density of 1.5 X 106 cells per 16 mm flat-bottomed well because this cell density and geometry has been shown to be optimal for antigen-induced, antigen-specific responses with a relative lack of polyclonal responses (15) . Various cell fractions were cultured at different densities that had been determined to be optimal for the given fraction. The TCE fractions were cultured at I X 106 cells per well and the TCD fractions at 0. Cultures for measuring routine blast transformation were performed, as previously described, in 96-well round-bottomed microtiter dishes (Linbro Chemical Co., Hamden, CT) containing 1 X 10' cells per well in 0.1 ml RPMI with 15% human A serum (29 Ml of solution containing p-nitrophenylphosphate (1 mg/ml) (Sigma Chemical Co.) in carbonate buffer, pH 8.6, with 0.001 M MgCl2 was added to each well, and the plate was sealed with pressure-sensitive film. The plate was then stored in the dark at room temperature and periodically evaluated for the development of color (usually 2-6 h). The outside wells were not used because of the higher backgrounds noted in these wells. The subsequent development of color was detected on a multichannel spectrophotometer (Dynatech Laboratories, Inc.) and compared with a standard prepared by dilution of human hepatitis B Ig (lot C5729A; Cutter Laboratories, Inc., Berkeley, CA) in 10% FCS in RPMI. The spectrophotometer was blanked on a 10% FCS RPMI control before reading of the plate. A dilution of 10-7 was arbitrarily assigned a value of 1 U of antibody to HBsAg. An ELISA to measure total supernatant IgG production was employed as previously described in detail (14, 15) .
A commercially available radioimmunoassay to measure anti-HBs Ig (Ausab) was employed to measure the level of anti-HBs IgG in serum samples. The results were expressed as a ratio of counts per minute of the sample to the counts per minute of a standard negative control. The cut-off point for a negative serum sample was 2.1 times the mean value of the negative controls.
Blast 
Results
In vitro induction of anti-HBs IgG. The anti-HBs IgG and total IgG responses to in vitro stimulation with HBsAg and PWM in a temporal relationship to booster immunization are seen in Fig. 1 . The mean serum anti-HBs serum titer after the first immunization, as measured in the Ausab radioimmunoassay, was 11.1±5.1 in the six individuals studied in Fig. 1 as compared with 10.7±4.3 for the remaining eight individuals (P > 0.2). This observation suggests that there was no significant selection bias in studying these 6 individuals, compared with the total study group of 14 responders as a whole. Before immunization (Fig. 1 A) no specific antibody was detected even in the cultures stimulated with the T cell-dependent polyclonal B cell activator PWM (P > 0.2). By 2 wk after immunization (Fig. 1 B) there was marked spontaneous production of anti-HBs IgG culture, which could not be further enhanced by the presence of PWM or HBsAg (P > 0.2). There was a striking shift in the patterns of anti-HBs IgG production by 4 wk after immunization (Fig. 1 C) . Little spontaneously secreted anti-HBs IgG was detectable at this point (P > 0.2). There was, however, a striking induction of anti-HBs IgG production by HBsAg (P < 0.01). This antigen-induced antiHBs IgG response was not part of an overall polyclonal response because the total amounts of IgG in the unstimulated (control) and antigen-stimulated cultures were similar (P > 0.2). Thus, the in vitro stimulation of PBMCs with HBsAg after immunization with HBsAg vaccine resulted in an increase in specific IgG production as part of an oligoclonal response. By 8 wk after immunization the antigen-induced anti-HBs IgG response could no longer be demonstrated (P > 0.2), despite the fact that PWM could stimulate cells to secrete HBsAg-specific IgG (Fig. 1 D) . Note that three of five individuals tested 5 mo or more after the last booster immunization demonstrated an HBsAg-induced production of anti-HBs IgG (data not shown). In the single individual tested at all time points after both the second and third immunizations, the pattern of: (a) increased spontaneous secretion of anti-HBs IgG at 2 wk; (b) antigen-induced anti-HBs IgG response at 4 wk; and (c) the absence of an antigen-induced response, despite the stimulation of anti-HBs IgG with PWM at 8 wk, was demonstrated after each booster immunization. Although stimulation with 0.1 tg/ml HBsAg resulted in peak stimulation of anti-HBs IgG (Fig. 1 C) , the induction of specific antibody could also be demonstrated for 1 gg/ml (26 (Fig. 2) . In the absence of monocytes, the induction of specific antibody production by antigen or PWM could not be demonstrated (P < 0.01). The induction of in vitro anti-HBs IgG by HBsAg also depends upon the presence of T lymphocytes (all P _ 0.04) (Fig. 3) . Neither B cells plus monocytes nor T cells plus monocytes could be triggered by antigen alone to produce specific antibody (P > 0. (Fig. 4) . The TCE fractions were treated with different doses of irradiation. There was a striking dichotomy in the sensitivity of the T helper cell signals to irradiation. At 2,000 rads there was marked potentiation of the PWM-stimulated response and substantial suppression of the antigen-induced response.
Induction of anti-HBs IgG production in the absence of HBsAg. An MLR supernatant was enough to induce the production of anti-HBs IgG in the absence of T cells and antigen (P < 0.05) (Fig. 5) . Furthermore, the addition of low concentrations of TT antigen to PBMC cultures of subjects recently immunized (within 1 yr) to TT as well as with HBsAg vaccine could stimulate anti-HBs IgG production (Fig. 6) . Taken together, these observations suggest that the B cells responsible for the specific antibody production are fairly advanced in the B cell activation/proliferation/differentiation sequence (32) produce strong proliferative responses was demonstrated. In fact, the higher doses of KLH, which produce the optimal proliferative responses, profoundly suppress the antigen-induced antibody responses. In contrast to the KLH system, no proliferative responses to HBsAg could be clearly demonstrated across a broad range of concentrations (P > 0.2) (Fig. 7) . This lack of a demonstrable proliferative response to HBsAg was not due to a shift in the usual kinetics of the in vitro blastogenic response to antigens since no response was detectable across a broad time kinetic curve when it was compared with the kinetic curve seen with responses to stimulation with TT (Fig. 8) . To (Table I ) and in the presence of indomethacin (Table II) were performed. Neither partial adherence cell depletion nor the presence of indomethacin enhanced the proliferative response to HBsAg. Finally, to exclude nonspecific suppressive and/or toxic responses, the effects of the addition of HBsAg on the proliferative response of PBMC to TT antigens were studied (Fig. 9) . No In the present study we have clearly demonstrated that after immunization with HBsAg vaccine it is possible to induce specific anti-HBsAg IgG responses by in vitro stimulation with low concentrations of HBsAg. The induction of specific antiHBs IgG responses is both T cell and monocyte dependent and requires defined antigen concentration for an optimal response. Note that specific anti-HBs IgG in vitro responses are strikingly dependent on the time after booster immunization at which PBMCs are obtained. 2 wk after booster immunization there appear in the circulating lymphocyte pool B cells that are activated and that can spontaneously secrete anti-HBsAg IgG. Because these B cells are already activated and far advanced along the differentiation pathways, as witnessed by the fact that they are spontaneously secreting antibody, additional stimulation with antigen or PWM does not further enhance, and in some cases suppresses, the response. By 4 wk after booster immunization there is a marked decline in spontaneous anti-HBs IgG production. However, the HBsAginduced production of anti-HBs IgG can be readily demonstrated at this point. Furthermore, stimulation with a polyclonal activator also results in an increased production of anti-HBs IgG, which is part of an overall increase in total IgG production.
The time point after booster immunization at which responses are measured is truly critical. In one individual studied 3 wk after booster, a pattern of increased spontaneous antiHBs IgG and an absence of the antigen-induced response was demonstrated. 4 d later, spontaneous antibody production was no longer detectable, and an antigen-induced, antigen-specific response was readily demonstrated. Note that the peak in vivo kinetic response for the antigen-induced, anti-HBs IgG response occurred later than the in vivo peak response reported in the KLH system, which was 2 wk after booster immunization (15) . Differences in the antigen employed, immunization protocol, isotype of Ig measured, and dose of antigen used for immunization could explain this discrepancy between the two systems. By 8 wk after immunization, HBsAg-induced antiHBs IgG could no longer be demonstrated despite the presence of B cells in the peripheral blood compartment that could be polyclonally activated by PWM to secrete anti-HBs IgG. The reason for the absence of the antigen-induced specific response at this kinetic point has not been clearly defined. Whether there is an absence of the appropriate T cell or B cell population in the peripheral blood compartment remains to be determined. The absence of B cells in the peripheral blood compartment that can respond to specific antigenic signals has been suggested as a possible cause for unresponsiveness in one antigen-driven system (33). Alternatively, preliminary evidence in our laboratory in the KLH antigen-induced system suggests that the absence of antigen-responsive T cells from the peripheral blood compartment may be responsible for the absence of antigen-induced specific Ig production (Lane, H. C., and A. S. some previously immunized individuals. This observation is in concordance with the ability to stimulate antigen-induced specific antibody responses to KLH -1 yr after immunization after a long refractory period (34 Days in Culture the T cell signals for anti-HBs IgG production after stimulation with the polyclonal activator PWM versus HBsAg is strikingly dissimilar (Fig. 4) . When T cells were irradiated (2,000 rads), the production of specific IgG after stimulation with PWM increased substantially; in sharp contrast, anti-HBs IgG production after stimulation with antigen declined significantly. The relatively greater sensitivity to the effects of irradiation of the net T cell helper signal (the balance between helper and suppressor signals) in the antigen-induced system, when compared with the PWM-induced system, is similar to the pattern reported in other in vitro antigen-induced antibody systems (15-17, 19, 36 The human immune response, including cellular immune reactivity to HBsAg, has been extensively evaluated by a variety of techniques, including migration inhibition, cytotoxicity assays, and blast transformation after infection with hepatitis B virus (reviewed, 9 and 10). In the convalescent phase after resolution of hepatitis B viral infection, blastogeneic responses to HBsAg have been reported by some (46-48) but not all authors (49) . In the papers that report positive results, the stimulation index has been relatively low (usually .5). The reasons for the disparate results are unclear, but technical differences in studies, including the serum source used for culture, the source, dose, and purity of HBsAg, as well as other experimental parameters, may be relevant. In this regard, the description of a serum protein in the blood of some patients with hepatitis B viral infection that can modulate T lymphocyte receptors (50, 51) and the description of an albumin receptor on HBsAg (52, 53) clearly emphasize the unique and complex nature of the interaction between hepatitis B virus and the human host.
In this report, we have demonstrated the ability to evaluate antigen-specific immune response to HBsAg at the B cell and T cell level. The studies reported here provide a model system to examine the complexities of the immune response to HBsAg and may prove useful in dissecting out the aberrations of the immune response to this clinically relevant antigen which may be involved in immune-mediated diseases associated with hepatitis B virus infection (1) (2) (3) (4) (5) (6) .
